Sjögren Syndrome with Peripheral Multineuritis and Active Systemic Disease

When Sjögren syndrome is complicated by peripheral multineuritis in the setting of active systemic disease, treatment decisions require careful attention to organ-specific severity and a structured therapeutic approach.

Clinical Scenario

This protocol covers Sjögren syndrome presenting with peripheral multineuritis alongside active systemic disease. Neuropathic involvement in this context — including cryoglobulinemic-related multineuritis — requires treatment tailored to organ-specific severity, assessed using the ESSDAI (EULAR Sjögren's Syndrome Disease Activity Index) framework.

Treatment Approach (Partial Overview)

Management centres on glucocorticoid-based therapy, with the specific regimen determined by disease severity. The full protocol — including the complete sequence of options and all clinical guidance — is available via the link below.

Treatment Goal

The primary measurable target is a reduction of ≥3 points in the global ESSDAI score, indicating meaningful systemic disease control.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1136/annrheumdis-2019-216114

Neuropathy (including ganglionopathy and polyradiculopathies) with severe motor deficit/ataxia; cryoglobulinemic-related multineuritis.
Treatment of systemic disease should be tailored to organ-specific severity using the ESSDAI definitions.
GCs should be used at the minimum dose and length of time necessary to control active systemic disease.
GC (recommended dose in mg/kg/day); short-term course whenever possible; consider methylprednisolone pulses in severe cases.

View source ↗